Glaukos

Business

JP Morgan raises Glaukos to buy; cites potential of iDose, iStent (NYSE:GKOS)

phive2015 JP Morgan raised its rating of Glaukos (NYSE:GKOS) to overweight, citing the company’s recently approved ophthalmology product iDose. The…

Read More »
Business

Truist starts Glaukos at buy, cites glaucoma market opportunity (GKOS)

FG Trade/E+ via Getty Images Truist has initiated coverage of Glaukos (NYSE:GKOS) with a buy rating, citing the company’s glaucoma…

Read More »
Back to top button